Pfiz­er pumps $120M in­vest­ment in­to Kala­ma­zoo plant for Paxlovid pro­duc­tion

As Pfiz­er is con­tin­u­ing to dou­ble down on its Paxlovid ef­forts, more room at its fa­cil­i­ty in Michi­gan will now be re­quired.

The phar­ma will be com­mit­ting $120 mil­lion on its own to its 1,300-acre man­u­fac­tur­ing fa­cil­i­ty in Kala­ma­zoo, MI to en­able US-based pro­duc­tion in sup­port of its Covid-19 oral an­tivi­ral.

Ac­cord­ing to the phar­ma­ceu­ti­cal gi­ant, the in­vest­ment will ex­pand the pro­duc­tion of the API and RSMs used in the man­u­fac­ture of nir­ma­trelvir, a key com­po­nent in Paxlovid. The com­pa­ny ex­pects the ex­pan­sion will cre­ate more than 250 ad­di­tion­al jobs at the Kala­ma­zoo site.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER